LysOmega® | An LPC Rich Omega-3® Powered by VESIsorb® Technology

It is widely accepted in the scientific community that omega-3 essential fatty acids display variable absorption and bioavailability which is their pharmacokinetics (PK).

Further, omega-3 essential fatty acids, and their ability to cross the blood brain barrier (BBB) or reach other vital tissues and organs is extremely limited without specific transporter mechanisms such as MFSD2A. SourceOne has addressed this unmet need with the launch of our first LysOmega^® softgel formulation - formulated with high levels of DHA fish oil molecularly bound to phospholipids and LPC.  

The formulation is the result of a four-year research and product development program addressing the challenges omega-3 essential fatty acids face in crossing the blood-brain and blood-retina barriers.

Our LysOmega^® formulation uses the clinically proven VESIsorb^® delivery system to support enhanced absorption and targeted DHA and EPA transport to the brain, retina, and other vital tissue.

The LysOmega^® launch represents a first-to-market opportunity with an LPC-rich omega-3^® formula validated for compatibility with a clinically proven drug delivery system.

Prior research suggests VESIsorb^® technology will deliver higher LPC-omega-3 levels in the plasma, leading to a higher concentration of LPC-omega-3 at the MFSD2A transporter surface, which may in turn result in higher concentrations in the central nervous system (CNS).

Key Features

• The highest DHA in an LPC Rich Omega-3^® formula correlating to hundreds of longevity and cognitive health studies.
• Patented enzymatic process for fish oil phospholipid production.
• Powered by VESIsorb^®, which has demonstrated up to 26X AUC improvements.
• Effective absorption even when taken without a high-fat meal, overcoming a common obstacle with standard omega-3 ethyl ester and triglyceride products.
• VESIsorb^®, a Swiss-developed delivery system with more than 35 years of safe and effective commercial use, has been clinically proven to improve the AUC of omega-3 fatty acids by up to 26-fold in the plasma, as demonstrated in a pharmaceutical omega-3 pharmacokinetic study (n=165) conducted by NutraSource.

Improved bioavailability from VESIsorb^® directly translates to delivering higher blood plasma levels of DHA and EPA with a much lower dose.

• Predictable plasma levels, independent of food/fat status.
• Fewer servings required to achieve the desired therapeutic effect.
• Superior loading for smaller and easier to consumer capsules.
• Addresses issues related to poor absorption like age, diet, and gender.
  

There’s never been a better time to launch LPC Rich Omega-3^® products, and no one is better prepared for this opportunity than SourceOne and our global partnerships.

Have Questions About LysOmega^®?

Interested in learning more about LysOmega^®, its scientific foundation, formulation applications, or commercial availability? Contact our team.

‍